Visceral fat (VF) increases with the menopause and is an independent predictor of the metabolic syndrome, diabetes, and cardiovascular disease (CVD) in women. Little is known about how hormonal changes during the menopausal transition are related to the increase in VF. We aimed to determine the relationship between bioavailable testosterone and VF in middle‐aged women at various stages of the menopausal transition and whether this relationship is independent of age and other CVD risk factors. The Study of Women's Health Across the Nation (SWAN) is a longitudinal, community‐based study. This report uses baseline data from a population‐based longitudinal ancillary study at the Chicago site to examine the cross‐sectional relationship between testosterone and computed tomography (CT)–assessed VF in women at different stages of the menopausal transition. Included are 359 women (47.2% black), aged 42–60 years, who were randomly selected from a complete community census in which a 72% participation rate was achieved. In multivariate models, bioavailable testosterone was associated with VF independent of age, race, percent total body fat, and other cardiovascular risk factors. Bioavailable testosterone was a stronger predictor than estradiol and was interchangeable in its strength of association with sex hormone–binding globulin (SHBG). As bioavailable testosterone was associated with VF even after adjusting for insulin resistance, this suggests that it plays an important role in regional fat distribution. Our findings may have direct implications in explaining the effect of menopause‐related testosterone predominance on VF accumulation and subsequent cardiovascular risk.
Sex-specific care of musculoskeletal impairments is an increasingly important topic in women's health. This is clinically relevant and of paramount importance as it pertains to diagnosis and treatment of musculoskeletal and peripheral neurologic disorders of pregnancy and the puerperium. It is estimated that virtually all women experience some degree of musculoskeletal discomfort during pregnancy, and 25% have at least temporarily disabling symptoms. This review provides information on common pregnancy-related musculoskeletal conditions, including a discussion of anatomy and physiology, diagnosis, prognosis, and treatment of these disorders.
Objective-Mechanisms underlying the association between depression and increased cardiovascular risk remain poorly understood. Central adiposity is one potential pathway. Prior research has shown an association between depression and central adiposity but few studies have examined whether depressive symptoms are differentially associated with visceral adipose tissue (VAT), which is more metabolically active and confers greater cardiovascular risk than subcutaneous fat (SAT).Methods-We investigated the cross-sectional association between depressive symptoms, assessed by the Center for Epidemiological Studies Depression Scale (CES-D), and VAT and SAT, assessed by computed tomography, in a sample of 409 middle-aged women (44.7% African-Americans, 55.3% whites; mean age=50.4 years) participating in the Chicago site of the Study of Women's Health Across the Nation (SWAN).Results-With adjustments for age, race, total percent fat and sex hormone binding globulin (SHBG), each 1-point higher score on the CES-D was associated with 1.03 cm 2 greater VAT (p<. 001). Women with a CES-D score of 16 or greater, indicative of clinically relevant depressive symptomatology, had 24.5% more VAT than women with lower CES-D scores (p<.001). Further adjustment for Framingham Risk Score and physical activity did not alter the findings, and associations did not vary by race. Associations were strongest in obese and overweight women. Depressive symptoms were unrelated to SAT.Address correspondence and reprint requests to: Susan A. Everson-Rose, Ph.D., University of Minnesota, 717 Delaware St SE, Room 166, Minneapolis, MN 55414,, saer@umn.edu. Dr. Everson-Rose was affiliated with Rush University Medical Center when this work was initiated but completed the work after relocation to the University of Minnesota.Portions of this work were presented at the 64 th annual meeting of the American Psychosomatic Society, Denver, CO, 3/4/06 and are published in abstract form (Psychosom Med 2006;68:A-27 NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptConclusions-Increased visceral fat may be one pathway by which depression contributes to excess risk for cardiovascular disease and diabetes. Further research is needed to examine whether depressive symptoms influence accumulation of VAT over time. KeywordsAbdominal obesity; depressive symptoms; African-American; women's health; cardiovascular disease Consistent evidence has accumulated over the past two decades showing that depression or depressive symptoms are related to increased risk of cardiovascular disease (CVD) morbidity and mortality (1) and diabetes (2,3). The pathways or mechanisms that underlie or mediate the association of depression or depressive symptoms with CVD and diabetes -though widely studied -are incompletely understood. The purpose of this study was to examine the relation of depressive symptoms with central adiposity, one pathway by which depression and depressive symptoms may contribute to CVD and diabetes risk.Central adiposity is more atherogenic...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.